---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-23-000088"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2023-12-22T23:59:59+00:00"
generated_at: "2026-06-07T07:57:42.392100+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics loses Huadong license for TTP273; director Harjivan resigns

## Summary
- Huadong terminates TTP273 license for China/Pacific Rim; Huadong discontinues development.
- Termination effective after negotiation of final agreement; process ongoing.
- Director Chandresh Harjivan resigns from board, no disagreement.

## SEC filing metadata
- accession: 0001641489-23-000088
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2023-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000088/0001641489-23-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000088/vtvt-20231218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-23-000088
- JSON: https://secwatch.observer/filing/0001641489-23-000088.json
- Plain text: https://secwatch.observer/filing/0001641489-23-000088.txt

## Key facts
- Executive change
  Chandresh Harjivan resigned as member of the board of directors at vTv Therapeutics Inc..
  - Action: resigned
  - Role: member of the board of directors
  source text: On December 18, 2023, Chandresh Harjivan resigned as a member of the board of directors (the “Board”) of the Company to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000088/0001641489-23-000088-index.htm
- Material Agreements
  vTv Therapeutics Inc. terminated License Agreement between vTv Therapeutics LLC and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. valued at Notice of intent to terminate received on December 18, 2023; termination effective after negotiation (effective 2023-12-18).
  - Action: termination
  - Agreement: license
  - Counterparty: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
  - Value: Notice of intent to terminate received on December 18, 2023; termination effective after negotiation
  - Effective: 2023-12-18
  source text: On December 18, 2023, vTv Therapeutics LLC (“vTv LLC”), a controlled subsidiary of vTv Therapeutics Inc. (the “Company”), received notice from Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) of their intent to terminate the License Agreement between vTv LLC and Huadong, dated as of December 21, 2017, as amended January 14, 2021 (the “Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000088/0001641489-23-000088-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.